Literature DB >> 17024350

Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria.

Kristina A Strnadová1, Felix Votava, Jan Lebl, Adolf Mühl, Chike Item, Olaf A Bodamer, Toni Torresani, Ivan Bouska, Franz Waldhauser, Wolfgang Sperl.   

Abstract

This study aimed to estimate the number of infants who died of unrecognized congenital adrenal hyperplasia (CAH) in Austria and the Czech Republic within the past 13 years, before the introduction of adequate neonatal screening. The study was based on retrospective analysis of neonatal screening cards of 242 infants who died suddenly between 7 days and 12 months of age and whose cause of death could not be identified. 17-hydroxyprogesterone (17-OHP) was measured by fluoroimmunoassay and positive samples were subsequently genotyped. Three infants out of 242 may have had unrecognized CAH due to CYP21 (steroid 21-hydroxylase) gene defect. Their newborn 17-OHP levels and CYP21 genotypes were 706 nmol/l and del/conv//del/conv, 53 nmol/l and I2//I2, and 811 nmol/l and I2//Gln318stop, respectively. CAH due to CYP21 defect can lead to sudden unexpected death without prior symptoms typical for the condition. Hence, newborn screening would have prevented these deaths had it been available. In addition, we have shown that the I2 point mutation that is expected to lead to simple virilizing form may lead to a fatal outcome.

Entities:  

Mesh:

Year:  2006        PMID: 17024350     DOI: 10.1007/s00431-006-0154-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Stability of 17alpha-hydroxyprogesterone in dried blood spots after autoclaving and prolonged storage.

Authors:  Dóra Török; Adolf Mühl; Felix Votava; Georg Heinze; János Sólyom; Julia Crone; Sylvia Stöckler-Ipsiroglu; Franz Waldhauser
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

2.  Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value.

Authors:  Bernhard Olgemöller; Adelbert A Roscher; Bernhard Liebl; Ralph Fingerhut
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

3.  Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries.

Authors:  J Kovács; F Votava; G Heinze; J Sólyom; J Lebl; Z Pribilincová; H Frisch; T Battelino; F Waldhauser
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

4.  Evaluation of neonatal screening for congenital adrenal hyperplasia.

Authors:  J W Honour; T Torresani
Journal:  Horm Res       Date:  2001

5.  Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.

Authors:  J Fitness; N Dixit; D Webster; T Torresani; R Pergolizzi; P W Speiser; D J Day
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

Review 6.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P C White; P W Speiser
Journal:  Endocr Rev       Date:  2000-06       Impact factor: 19.871

7.  Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.

Authors:  B L Therrell; S A Berenbaum; V Manter-Kapanke; J Simmank; K Korman; L Prentice; J Gonzalez; S Gunn
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

8.  Cardiac arrest in an infant with congenital adrenal hyperplasia.

Authors:  W Ruppen; N Hagenbuch; M Jöhr; P Christen
Journal:  Acta Anaesthesiol Scand       Date:  2003-01       Impact factor: 2.105

9.  Sudden infant death syndrome and unclassified sudden infant deaths: a definitional and diagnostic approach.

Authors:  Henry F Krous; J Bruce Beckwith; Roger W Byard; Torleiv O Rognum; Thomas Bajanowski; Tracey Corey; Ernest Cutz; Randy Hanzlick; Thomas G Keens; Edwin A Mitchell
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

Review 10.  Congenital adrenal hyperplasia: phenotype and genotype.

Authors:  Ieuan Hughes
Journal:  J Pediatr Endocrinol Metab       Date:  2002-12       Impact factor: 1.634

View more
  7 in total

Review 1.  The next 150 years of congenital adrenal hyperplasia.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  J Steroid Biochem Mol Biol       Date:  2015-06-03       Impact factor: 4.292

2.  Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance.

Authors:  Felix Votava; Dana Novotna; Petr Kracmar; Hana Vinohradska; Eva Stahlova-Hrabincova; Zuzana Vrzalova; David Neumann; Jana Malikova; Jan Lebl; Dietrich Matern
Journal:  Eur J Pediatr       Date:  2012-01-11       Impact factor: 3.183

3.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 4.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  Perrin C White
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

5.  Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.

Authors:  Lisa A Prosser; Scott D Grosse; Alex R Kemper; Beth A Tarini; James M Perrin
Journal:  Genet Med       Date:  2012-04-05       Impact factor: 8.822

6.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

7.  Application of the new classification on patients with a disorder of sex development in indonesia.

Authors:  A Zulfa Juniarto; Yvonne G van der Zwan; Ardy Santosa; Remko Hersmus; Frank H de Jong; Renske Olmer; Hennie T Bruggenwirth; Axel P N Themmen; Katja P Wolffenbuttel; Leendert H J Looijenga; Sultana M H Faradz; Stenvert L S Drop
Journal:  Int J Endocrinol       Date:  2011-12-29       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.